Great article. Learned a lot reading it.
Yes, worth reading the whole thing. One troubling takeaway, assuming the person quoted is correct, is that the big upcoming European clinical trial seems to be slanted against HCQ.
For one thing, they’re not including azithromycin. And they’re not administering HCQ until the patient has very low oxygen levels. That is, when they’re pretty far into the progression and their lungs are starting to fail. HCQ is only effective when given shortly after first symptoms start to appear.